Needham & Company LLC lowered shares of Inogen (NASDAQ:INGN) from a buy rating to a hold rating in a report published on Wednesday, Briefing.com Automated Import reports.
Several other equities analysts have also recently weighed in on the stock. BidaskClub raised shares of Inogen from a strong sell rating to a sell rating in a research report on Saturday, July 27th. Stifel Nicolaus dropped their price target on shares of Inogen from $160.00 to $85.00 and set a buy rating on the stock in a research report on Wednesday, May 8th. Finally, JPMorgan Chase & Co. cut shares of Inogen from a neutral rating to an underweight rating and set a $72.00 price target on the stock. in a research report on Wednesday, July 3rd. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the company. Inogen has an average rating of Hold and an average price target of $82.17.
NASDAQ INGN traded down $1.72 during trading hours on Wednesday, hitting $44.94. The company’s stock had a trading volume of 677,005 shares, compared to its average volume of 558,134. Inogen has a 52 week low of $41.19 and a 52 week high of $287.79. The stock has a market capitalization of $928.04 million, a P/E ratio of 19.54, a PEG ratio of 1.67 and a beta of 1.40. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.35 and a quick ratio of 6.70. The company’s 50-day moving average price is $61.84.
Several institutional investors have recently bought and sold shares of the business. Oregon Public Employees Retirement Fund increased its stake in shares of Inogen by 1.9% during the 1st quarter. Oregon Public Employees Retirement Fund now owns 7,029 shares of the medical technology company’s stock worth $670,000 after purchasing an additional 132 shares during the last quarter. Arizona State Retirement System increased its stake in shares of Inogen by 1.4% during the 1st quarter. Arizona State Retirement System now owns 12,845 shares of the medical technology company’s stock worth $1,225,000 after purchasing an additional 178 shares during the last quarter. Advisor Group Inc. increased its stake in shares of Inogen by 71.4% during the 2nd quarter. Advisor Group Inc. now owns 461 shares of the medical technology company’s stock worth $31,000 after purchasing an additional 192 shares during the last quarter. Stifel Financial Corp increased its stake in shares of Inogen by 8.5% during the 4th quarter. Stifel Financial Corp now owns 2,867 shares of the medical technology company’s stock worth $355,000 after purchasing an additional 224 shares during the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Inogen during the 1st quarter worth approximately $25,000. 98.63% of the stock is currently owned by hedge funds and other institutional investors.
Inogen Company Profile
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Further Reading: What is the CBOE Russell 2000® Volatility Index?
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.